Imiquimod, TLR7 ligand

Novus Biologicals | Catalog # NBP2-26228

Novus Biologicals
100% Guarantee

Key Product Details

Species

Human, Mouse

Applications

Functional Assay

Product Summary for Imiquimod, TLR7 ligand

Imiquimod, TLR7 ligand is an imidazoquinoline amine analog to guanosine. As a synthetic molecule of the Imidazoquinoline family, it has potent immunostimulatory activity. Imiquimod has been shown to activate only TLR7. This activation is MyD88 dependant and leads to the induction of the transcription factor NF-kB.

Product Specifications

Specificity

Imiquimod is human/mouse TLR7 agonist.

Application Notes

Formula: C14H16N4, HCl. Molecular weight: 276.8. This product is useful for activation of TLR7 and stimulation of TLR7 has been achieved with 5-10 ug/mL. Use in ligand activation, functional, and in vitro assays reported in scientific literature (PMID 25957979)

Scientific Data Images for Imiquimod, TLR7 ligand

Imiquimod, TLR7 ligand [NBP2-26228] - 293T cells were transfected with pCMV/TLR7 plasmid and pNF-kB/SEAP plasmid using Lipofectamin 2000. After 48 hrs of transfection, 5 ug/mL of Imiquimod (R-837) was added. Cells were incubated at 37C for 24 hrs. Transfected cell supernatant was collected and analyzed using NF-kB SEAPorter Assay kit.

Formulation, Preparation, and Storage

Formulation

NBP2-26228-0.125mg: 125 ug in 50 uL of DMSO (this product was formerly supplied in sterile water) NBP2-26228-1mg: 1 mg in 400 uL of DMSO.

Concentration

Please see the protocols for proper use of this product. If no protocol is available, contact technical services for assistance.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Imiquimod, TLR7 ligand

Imiquimod, TLR7 ligand, an imidazoquinoline amine analog to guanosine, is an immune response modifier with potent indirect antiviral activity. The antiviral activity of imiquimod was first shown in guinea pigs infected with herpes simplex virus [1]. Imiquimod is now an approved treatment for external genital warts caused by human papillomavirus infection. This low molecular synthetic molecule induces the production of cytokines such as IFN-Alpha. Unlike R848, Imiquimod activates only TLR7 but not TLR8 [2]. This activation is MyD88-dependent and leads to the induction of the transcription factor NF-kB [3].

Alternate Names

R 837, R837

Additional Imiquimod, TLR7 ligand Products

Product Documents for Imiquimod, TLR7 ligand

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for Imiquimod, TLR7 ligand

5 mg size will be provided as 5 x 1.0 mg vials.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Support products are guaranteed for 6 months from date of receipt.

Citations for Imiquimod, TLR7 ligand

Customer Reviews for Imiquimod, TLR7 ligand (1)

5 out of 5
1 Customer Rating
5 Stars
100%
4 Stars
0%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Imiquimod, TLR7 ligand?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 1 of 1 review Showing All
Filter By:
Clear Filters X
  • Imiquimod, TLR7 ligand
    Name: Anonymous
    Verified Customer | Posted 08/15/2017
    Imiquimod enhanced the osteo-differentiation ability of mesenchymal stem cells(MSC).
    Imiquimod was added into the medium at final concentration of 10 μg/ml. Imiquimod enhanced the osteo-differentiation ability of mesenchymal stem cells.
    Imiquimod, TLR7 ligand NBP2-26228

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All